More recently, the use of ABT-122, which is a novel dual variable-domain immunoglobulin against both TNFα and IL-17A, led to clinical outcomes similar to adalimumab in monotherapy in patients with RA [92]. The gene discussed is TNF; the disease is rheumatoid arthritis.